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The aim of this study was to describe the double peak plasma
pharmacokinetic profile of ranitidine after oral administration to
healthy volunteers using non-compartmental and compartmental
analysis. A single 300 mg dose of ranitidine was given to ten healthy
volunteers (5 male and 5 female). Blood samples were drawn at
different times and analyzed by HPLC. Plasma profiles were
evaluated by non-compartmental and compartmental approaches.
The non-compartmental parameters determined were k (0.0054 ±
0.0010 min-1), t1/2 (2.2 ± 0.4 h), Vdss/F (265.3 ± 70.6 L), Cl/F (84.8
± 24.3 L/h) and AUC (225916 ± 54099 ng*min/mL). The
compartmental analysis was carried out using a two compartments
body model, with first order absorption from two different sites.
The parameters determined were k21 (0.0149 ± 0.0133 min
-1), ka1
(0.0117 ± 0.0073 min-1), ka2 (0.1496 ± 0.1699 min
-1), Vc (128 ±
75.2 L), a (0.0299 ± 0.0319 min-1), b (0.0074 ± 0.0014 min-1) and
time for the beginning of the absorption from the second site (126.7
± 58.1 min). The model used in the compartmental analysis was
adequate to describe the double peak of ranitidine plasma profile
and to determine the pharmacokinetic parameters.
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• Double peak plasma profile
INTRODUCTION
Ranitidine is histamine H2 receptor antagonist used
in the treatment of gastric disease related to acid gastric
hypersecretion (Grant et al., 1989).
Ranitidine pharmacokinetics has been evaluated in
many studies after intravenous and oral administration (Van
Hecken et al., 1982; Richards, 1983; Roberts, 1984; Grant
et al., 1989; Shim, Hong, 1989; Santos et al., 1996). The
plasma concentration-time profile of ranitidine after
intravenous administration shows a biexponential behavior
that is characteristic of a two compartment open model.
It has been shown in the literature that ranitidine
presents double peak profile after oral administration. These
pharmacokinetics profiles have been evaluated according to
a non-compartmental analysis for bioavailability and
bioequivalence determination (Hilgenstock et al., 1987).
Several mechanisms have been postulated to explain the
double peak phenomenon such as enterohepatic
recirculation, delayed gastric emptying, drug storage and
subsequent release from a post-absorptive depot, variable
absorption rates along the gastrointestinal tract, and
discontinuous absorption (Suttle et al., 1992; Suttle, Brouwer,
1994; Reynolds et al., 1998). In this way, ranitidine
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compartmental analysis requires the use of a modified
absorption equation that properly describes the double peak
observed. A compartmental analysis after oral administration
of this drug is not reported in the literature. Pharmacokinetic
compartmental analysis is important to allow forecasting
drug concentrations in the peripheral compartment for
pharmacokinetic-pharmacodynamic modeling (PK-PD
modeling) when the biophase is in a different compartment
than the blood (Stanski, 1991; Shargel, Yu, 1999).
Considering the status of ranitidine pharmacokinetics
evaluation, the aim of this study was to describe ranitidine
pharmacokinetics after oral administration to healthy
volunteers using non-compartmental and compartmental
analysis. The compartmental analysis was conducted aiming
to find an appropriate pharmacokinetic model to describe the
individual double peak plasma profiles observed for the drug.
METHODS
Subjects
Ten healthy volunteers (5 male and 5 female) with an
average age of 24.5 ± 2.7 years and an average body weight
of 65.0 ± 11.0 kg were included in the study. They were
selected based on their medical history, as well as physical
and clinical examination. Informed written consent was
obtained from all volunteers. The protocol was reviewed
and approved by the Ethics Committee of the University
Hospital (Hospital de Clínicas de Porto Alegre, Universida-
de Federal do Rio Grande do Sul, Brazil).
Study design
The subjects were instructed to avoid drug and
alcohol intake for a week before the study. In the day of the
experiment each volunteer received a single tablet of 300
mg of ranitidine (Glaxo Wellcome, Brazil) with 200 mL of
water at 9 am, after 8 hour fasting. Standard meals were
given after 4 hour of drug administration. Blood samples
were collected into heparinized tubes before and at 15, 30,
45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 360, 480 and
600 minutes after drug administration. Samples were
harvest into heparinized tubes, plasma was separated by
centrifugation and frozen to –20 ºC until analyzed.
Analytics
Ranitidine plasma concentration was determined by a
validated HPLC method (Koch et al., 1997). Briefly, plasma
(1 mL) was desproteinated with 4% perchloric acid and
centrifuged at 3000 rpm for 5 min. The supernatant (500 µL)
was neutralized with 500 µL of 1 M sodium carbonate. This
mixture (100 µL) was injected into the system which
consisted of a guard column Perisorb 30-40 µm 4 x 10 mm,
an analytical column Beta Basic RP8 5 µm 250 x 4.6 mm, a
pump Shimadzu LC-10AD, an ultraviolet detector Shimadzu
SPD-10A and an integrator Shimadzu C-R6A. The flow rate
was set to 1 mL/min and the mobile phase consisted of 0.05
M phosphate buffer (pH 4.0): acetonitrile (94:8 v/v).
The assay was validated according to the International
Conference of Harmonization (ICH) (Swartz, Krull, 1998).
The method showed to be linear over the range of 25 to
1400 ng/mL with correlation coefficients better than 0.9991.
The LOQ was 25 ng/mL. The intra-day precision was higher
than 94% while the inter-day precision was higher than 88%.
The accuracy was bigger than 95%. Since the acceptance cri-
teria for precision and accuracy is variation inferior to 15%
for both parameters (Shah et al., 1992), the method was con-
sidered adequate for the measurement of ranitidine in plasma.
Pharmacokinetic analysis
Individual plasma concentration-time profiles were
analyzed according to non-compartmental and compartmental
analysis. The independent model parameters determined were
the elimination rate constant (k), the half-life (t1/2), the relative
total clearance (Cl/F), the relative volume of distribution at
steady state (Vdss/F), the area under the concentration time
curve (AUC), area under the first moment curve (AUMC), and
the mean residence time (MRT) (Gibaldi, Perrier, 1982). The
plasma concentration peak (Cpmax) and the time to reach this
peak (Tmax) were obtained directly from the plots.
The compartmental analysis was carried out according
to a two-compartments open model with two first order
absorption rate constants from two different sites in the
gastrointestinal tract. The schematic representation of the
model is showed in Figure 1.
The equation that describes the drug concentration in
the central compartment of this model is shown below
(Wagner, 1993):
Equation 1
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FIGURE 1 - Scheme of the two compartments open model
with two parallel sites of absorption used in the
compartmental analysis. Xc and Xp = amount of drug in the
central and peripheral compartments, respectively; D = dose;
F = drug bioavailability, f = fraction of the drug absorbed at
each absorption site; ka1 = absorption rate constant at the first
absorption site, ka2 = absorption rate constant at the second
absorption site, tx = time for the second fraction of the drug to
begin to be absorbed; k12 = distribution rate constant from the
central to the peripheral compartment; k21 = redistribution rate
constant from the peripheral to the central compartment; k10
= elimination rate constant from the central compartment.
Adapted from Wagner, 1993.
where Cp is the drug plasma concentration, D is the dose
administrated, F is the drug bioavailability, f is the fraction
of the drug absorbed at each site, ka1 is the first absorption
rate constant, ka2 is the second absorption rate constant, tx
FIGURE 2 - Mean ranitidine plasma concentration versus time (left panel) and log mean plasma concentration versus
time (right panel) profiles obtained after the administration of a single 300 mg oral dose of ranitidine to 10 healthy
volunteers. Error bars indicate SD.
is the time for the second fraction of the drug to begin to
be absorbed, k21 is the redistribution rate constant from the
peripheral to the central compartment, a and b are the
hybrid constants for distribution and elimination phases,
respectively, Vc is the volume of distribution of the cen-
tral compartment, and t is the time.
The individual plasma profiles from the volunteers
were fitted to this model using the computer program
SCIENTIST® v. 2.0 (MicroMath, Salt Lake City). The
data points were no weighted for the analysis. The
goodness of fit was evaluated using the model selection
criteria (MSC) provided by the program. MSC is a
modified Aikake information criterion that allows
comparisons of variations data sets fitted to a selected
model. Increased MSC values indicate more appropriate
fits (SCIENTIST, 1995).
RESULTS
The average plasma concentration-time curves are
shown in Figure 2. The first average plasma concentration
peak (Cpmax1) was 765.4 ± 369.2 ng/mL and it was
observed at 75 ± 27 min (Tmax1). The second average peak
(Cpmax2) was 898.6 ± 348.6 ng/mL and it was observed at
172 ± 58 min (Tmax2). The plasma double peak was
observed in all volunteers but two, whose plasma profiles
showed a plateau in the time interval corresponding to the
second peak. Representative profiles of two volunteers
who presented doubled peak in plasma are presented in
Figure 3. The individual and averaged Cpmax and Tmax are
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TABLE I - Peak and time to peak values obtained from the plasma concentration-time curve of each volunteer after
administration of an oral dose of 300 mg of ranitidine
Subject Cpmax1 (ng/mL) Tmax1 (min) Cpmax2 (ng/mL) Tmax2 (min)
1 1111.5 90 567.7 236
2 439.1 45 1143.2 105
3 657.0 60 — —
4 898.8 60 435.8 150
5 458.8 105 1433.5 240
6 1220.0 105 — —
7 494.6 90 782.3 150
8 508.2 60 1221.6 150
9 445.6 30 953.3 105
10 1419.9 105 642.1 240
Average ± SD 765.4 ± 369.2 75 ± 27 898.6 ± 348.6 172 ± 58
FIGURE 3 - Ranitidine plasma concentration versus time
profiles obtained after the administration of a single 300 mg
oral dose of ranitidine to subject 5 ( ) and subject 8 ( ).
Santos et al., 1996). Since in our study the bioavailability
of ranitidine was not determined, the clearance and the
volume of distribution calculated are relative. Assuming
a bioavailability of 50%, reported for ranitidine after oral
administration (Roberts, 1984), the mean Cl obtained
would be 706.5 ± 202.7 mL/min which is in good
agreement with range of 600 to 700 mL/min reported in
the literature (Van Hechen et al., 1982; Roberts, 1984).
The same is valid for the volume of distribution (Vdss)
obtained which would be 132.7 ± 35.3 L, in a similar range
of values reported by other authors (1.2 to 1.9 L/kg) (Van
Hecken et al., 1982; Richards, 1983).
The double peak observed in the plasma profiles of
the volunteers after ranitidine oral administration is well
described in the literature, although some author did not
observed it in their studies (Lebert et al . ,  1981;
Hilgenstock et al., 1987). The diverse plasma peak
patterns observed by different authors have been related to
the blood sampling intervals, to the inter-subject variation
among the subjects employed in the studies and to the
analytic methods used to measure ranitidine in plasma.
Some authors related the second peak occurrence to the
food intake (Shim, Hong, 1989). However, in our study,
the food intake was allowed only four hours (240 min)
after drug dosing and the second peak occurred between
105 and 240 min.
Both Cpmax and both Tmax observed in this study
showed a big variability among the volunteers which can be
explained using the discontinuous absorption model
suggested by Suttle and co-workers (1992). In this model,
the gastrointestinal tract is divided into compartments
connected according to a catenary system and the drug
absorption occurs only in the first and in the last
compartment. According to simulations done by these
presented in Table I. The individual and average
pharmacokinetic parameters determined by non-
compartmental analysis are summarized in Table II.
The plasma concentration-time curve of each
volunteer was fitted to the two-compartments open model
described by Equation 1. The mean fit is shown in Figure 4.
The individual and average pharmacokinetic parameters
obtained from the fittings are depicted in Table III.
DISCUSSION
All parameters obtained in the non-compartmental
analysis were similar to those shown in literature
(Richards, 1983; Roberts, 1984; Desmond et al., 1990;
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TABLE II - Independent model parameters calculated from the plasma concentration-time curve of each volunteer after
administration of an oral dose of 300 mg of ranitidine
Subject K t1/2 AUC 0-∞ Cl/F* Vdss/F* AUMC0→∞ MRT
(min-1) (h) (ng.h/mL) (L/h) (L) (ng.h2/mL) (h)
1 0.0057 2.0 4673 64.2 188.0 203233 4.4
2 0.0040 2.9 4547 66.0 278.1 217595 4.8
3 0.0060 1.9 2668 112.5 314.1 104816 3.9
4 0.0065 1.8 2187 137.2 350.6 65318 2.9
5 0.0058 2.0 4473 67.1 193.5 231981 5.2
6 0.0047 2.5 3306 90.8 322.6 151232 4.6
7 0.0056 2.1 3698 81.1 240.9 170667 4.6
8 0.0042 2.7 4017 74.7 294.4 171170 4.3
9 0.0047 2.5 3250 92.3 328.8 118414 3.6
10 0.0073 1.6 4834 62.1 142.1 185364 3.8
Mean ± SD 0.0054 ± 0.0010 2.2 ± 0.4 3765 ± 855 84.8 ± 24.3 265.3 ± 70.6 161979 ± 52732 4.2 ± 0.6
* F = absolute bioavailability
authors using the discontinuous absorption model, the
intensity and variability of Cpmax and Tmax observed could be
attributed to the following factors: the dose administered,
the drug transfer rate from the stomach to the first site of
absorption, the number of gut compartments, the distance
between the two absorption sites, the drug transfer rate
among the compartments, and the absorption rate in each
site of absorption.
The compartmental analysis was carried out using
the individual plasma profiles. Although some studies
indicate that ranitidine behaves in the body as a two
compartments open model after intravenous administration,
the plasma concentration-time curves obtained in this study
after oral drug administration decline linearly as a single
order process. After oral administration, the mono or
biphasic declining of the drug plasma concentration-time
profile will depend upon the rate of drug absorption, the
number of samples taken within the collection period and
FIGURE 4 - Mean ranitidine plasma concentration versus time profile (left panel) and log mean plasma concentration
versus time profile (right panel) after the administration of a single 300 mg dose to 10 healthy volunteers fitted to a two
compartments open model with two sites of absorption (Eq. 1). Error bars indicate SD.
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TABLE III - Pharmacokinetic parameters obtained from the analysis of the individual plasma concentration profiles using
the two compartments model equation with two sites of absorption (Eq.1)*
Subject ka1 (min
-1) ka2 (min
-1) α (min-1) β (min-1) k21  (min
-1) f Vc/F (L) tx  (min)
1 0.0100 0.0046 0.0072 0.0075 0.0031 0.574 66.0 206
2 0.0082 0.3520 0.0646 0.0062 0.0370 0.656 105.2 90
3 0.0152 0.0053 0.0081 0.0080 0.0047 0.632 136.5 196
4 0.0232 0.0284 0.0246 0.0089 0.0149 0.806 166.9 120
5 0.0024 0.1912 0.0108 0.0085 0.0074 0.538 85.1 208
6 0.0035 0.2959 0.1021 0.0096 0.0391 0.623 56.8 89
7 0.0213 0.0271 0.0053 0.0052 0.0062 0.630 301.4 88
8 0.0137 0.4766 0.0073 0.0071 0.0063 0.461 169.4 143
9 0.0151 0.0456 0.0442 0.0061 0.0212 0.539 142.3 54
10 0.0041 0.0694 0.0254 0.0071 0.0093 0.782 50.4 73
Mean  ± SD 0.0117 0.1496 0.0299 0.0074 0.0149 0.62 128.0 127
± 0.0073 ± 0.1699 ± 0.0319 ± 0.0014 ± 0.0133 ± 0.11 ± 75.2 ± 58
* See text for legend
the relative magnitude of the micro-constants of the model
(k21, ka, k10). If the drug distribution occurs faster than the
absorption, the distribution phase will not be observed in the
plasma concentration profile because the system will not
provide enough time for the drug to distribute after
absorption (Liang, Derendorf, 1998; Shargel, Yu, 1999).
The choice of the adequate compartmental model to
analyze ranitidine profiles in this study was based on the
best fit to the double peak obtained for the model tested.
Although the concentration profiles show a log-linear
declining, the one compartment open model with two sites
of absorption did not fit well the double peak observed
even though the resulting MSC was 1.32 ± 0.57. The best
fit was obtained using the equation that describes the two
compartments open model with two sites of absorption, as
shown in Figure 4. The mean MSC value obtained was
1.94 ± 0.67 which was considered adequate for this
analysis.
As stated before, according to the discontinuous
absorption theory, in the two compartments model with
two sites of absorption, the gastrointestinal tract is divided
into different compartments but the absorption will occur
only in the first and in the last sites (Suttle et al., 1992)
(Figure 1). After the administration, the drug reaches the
first site of absorption and a fraction of the dose (f) is
absorbed. After absorption, this fraction of the drug
reaches the central compartment (Xc) and distributes to
the peripheral compartment (Xp) with a distribution rate
constant k12. The drug redistributes to the central
compartment with a rate constant k21, from where it will be
eliminated. After the first absorption, the fraction not
absorbed in the first site passes through the gut and
reaches the second site of absorption. In this site, the
fraction of the drug remained in the bowel (1-f) will be
absorbed and will be distributed in the body as the first
fraction.
Some evidences in the literature also corroborate the
choice for the discontinuous absorption model to describe
the data obtained in this study. According to Suttle and
Brouwer (1994) the gastric emptying or enterohepatic re-
circulation cannot contribute to the occurrence of a second
peak in the ranitidine plasma profile because the amount
of drug secreted in the bile in humans is to small, less than
3%, to promote a significant peak. Furthermore, the
concentration time profiles observed when the drug is
administrated directly in the stomach did not show two
peaks, indicating that the gastric emptying alone is not
enough to promote a secondary peak (Williams et al.,
1992).
Although there are no reports in the literature on the
compartmental analysis of ranitidine after oral
administration which could be used to compare the
pharmacokinetic parameters determined in this study, a
comparison between the compartmental and non-
compartmental results can be carried out. As expected, the
volume of distribution of the central compartment (Vc/F)
determined by the compartmental approach is smaller than
the Vdss/F calculated. The elimination rate constant (k)
determined in the non-compartmental analysis (0.0054 ±
0.0010 min-1) is similar to b-rate constant (0.0074 ± 0.0014
min-1), showing that the compartmental approach
appropriately described the elimination phase of the drug
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from the body. Finally, the time to begin the drug
absorption from the second absorption site (127 ± 58 min),
according to the model theory, is smaller than the time
observed for the drug to reach the second plasma peak
(172 ± 58 min). These observations corroborate the
adequacy of the compartmental model used to describe the
data obtained.
CONCLUSIONS
The parameters calculated in the non-compartment
analysis were similar to those reported in the literature
indicating that the data obtained from the volunteers in this
study are consistent with the previous reports. Eighth out
of ten plasma concentration profiles of ranitidine after oral
administration showed a double peak. This phenomenon
was described appropriately using the two compartmental
open model with two sites of absorption which considers
that the absorption occurs in two different places in the gut
as described by the discontinuous absorption theory. In
conclusion, the double peak observed in the ranitidine
plasma concentration could be explained mainly by the
discontinuous absorption theory.
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RESUMO
Análise compartimental do perfil de duplo pico
plasmático da ranitidina após administração oral a
voluntários sadios
O objetivo deste trabalho foi o duplo pico observado no
perfil farmacocinético plasmático da ranitidina após admi-
nistração oral a voluntários sadios através de análise
compartimental. Uma dose simples de 300 mg de ranitidina
foi administrada a dez voluntários sadios (5 homens e 5
mulheres). Amostras de sangue foram coletadas em diferen-
tes tempos e analisadas por HPLC. Os perfis plasmáticos
foram avaliados pela abordagem compartimental e não-
compartimental. Os parâmetros não compartimentais de-
terminados foram k (0,0054 ± 0,001 min-1), t1/2 (2,2 ± 0,4 h),
Vd/F (265,3 ± 70,6 L), Cl/F (84,8 ± 24,3 L/h) e AUC
(225916 ± 54099 ng*min/mL). A análise compartimental
foi conduzida utilizando-se o modelo de dois compartimen-
tos corporais com constantes de absorção de primeira or-
dem a partir de dois sítios de absorção diferentes. Os
parâmetros determinados foram k21 (0,0149 ± 0,0133 min-1),
ka1 (0,0117 ± 0,0073 min-1), ka2 (0,1496 ± 0,1699 min-1), Vc
(128 ± 75,2 L), a (0,0299 ± 0,0319 min-1), b (0,0074 ±
0,0014 min-1) e o tempo para o início da absorção no segun-
do sítio (126,7 ± 58,1 min). O modelo usado na análise
compartimental foi adequado para descrever o duplo pico
no perfil plasmático da ranitidina e para determinar os
parâmetros farmacocinéticos.
UNITERMOS: Ranitidina. Farmacocinética. Análise
compartimental. Duplo pico plasmático.
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